StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
068330.KQ$1202.00+0.33%
Fair $1202.00+0.0%

068330.KQ

ilShinbiobase Co. Ltd.

Unknown / UnknownKOSDAQ

$1202.00

+4.00 (+0.33%)

Fairly Valued+0.0%Fair Value $1202.00Fund rank 32/100 · Data gapFallback financials|
SA 30/D
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 25% · confianza 25%

FCF escenarios

weak_data · normalized FCF $5.2B · quality 59.3/100

Data gap 32/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 74/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

30/100

D

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 068330.KQLocal privado en este navegador · ilShinbiobase Co. Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$50.1B

P/E

10.5x

↑

EV/EBITDA

9.6x

↑

ROE

7.4%

↑

Gross Margin

53.1%

↑

Debt/Equity

N/A

•
52-Week Range$1202
$1081$2330

TradingView lightweight chart

068330.KQ price, volumen y niveles de valoración

Último $1,202Periodo +185.2%
Fair value: $1,202

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-10.7%

FCF CAGR

+35.2%

FCF margin

36.1%

FCF / Net income

1.09x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $14.53B · net income $4.79B · FCF $5.25B

2022-FY → 2025-FY

Gross margin

53.1%+1.7% pts

Operating margin

31.4%+6.1% pts

Net margin

33.0%+14.3% pts

FCF margin

36.1%+25.7% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$14.53B$14.53B$10.82B$16.44B$20.43B
Net Income$4.79B$4.79B$3.81B$6.23B$3.82B
EBITDA$5.00B$5.00B$2.70B$8.22B$5.17B
EPS115.00115.0091.00148.0089.00
Gross Margin53.1%53.1%58.0%57.4%51.4%
Operating Margin31.4%31.4%20.9%37.8%25.3%
Net Margin33.0%33.0%35.2%37.9%18.7%
Balance Sheet
Debt/Equity————0.00
Cash Flow
Free Cash Flow$5.25B$5.25B$4.07B$5.66B$2.12B
Returns
ROE7.4%7.4%6.3%10.9%7.1%
Valuation
P/E10.4510.4511.679.9517.42
EV/EBITDA9.639.6315.827.1711.76
P/B0.770.770.741.091.23
Growth & Yield
Revenue Growth34.3%34.3%-34.2%-19.6%—
EPS Growth26.4%26.4%-38.5%66.3%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-2.5%

fácil

EPS terminal req.

$106.66

Spread vs growth

28.9%

5Y implied EPS CAGR

2.3%

fácil

EPS terminal req.

$129.06

Spread vs growth

24.0%

10Y implied EPS CAGR

6.1%

razonable

EPS terminal req.

$207.85

Spread vs growth

20.3%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +10.0%

Total return

+10.0%

Start / end P/E

12.0x → 10.5x

EPS bridge

91.00 → 115.00

Residual

-3.4%

EPS growth+26.4%
Multiple rerating-13.0%
Dividend+0.0%
Residual / FX / buybacks / cross-term-3.4%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.